Scandinavian ChemoTech's subsidiary Vetiqure AB begins its marketing in the US
As part of the feasibility study underway in the US ahead of the launch of the company's unique TSE (Tumour Specific Electroporation) technology, intended for the treatment of pets affected by cancer, Vetiqure AB plans to participate in a number of Veterinary Conferences during the autumn.
The feasibility study, which started during the summer and will lead to a successful launch strategy in the USA, will enter a new phase during the autumn, where vetIQure™ will be shown to a larger group of veterinarians for the first time.
Through its presence, the company wishes to introduce and demonstrate its completely new TSE technology. TSE - with its unique dynamic and safety features - aims to improve the treatment effect and at the same time reduce the unwanted destruction that sometimes occurs with the previous and static equipment.
"It will be very interesting to see how the American veterinarians receive our innovation and at the same time find out what opportunities the conferences will offer to our launch." - says Mohan Frick, CEO
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.